CLINICAL TRIALS PROFILE FOR TEGRETOL-XR
✉ Email this page to a colleague
All Clinical Trials for TEGRETOL-XR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000441 ↗ | Drug Therapy for Alcohol Detoxification | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 4 | 1969-12-31 | This project will provide relevant clinical information for primary care practitioners treating alcohol withdrawal syndrome in outpatient settings. This double-blind, placebo- controlled clinical trial will compare the effectiveness of lorazepam (Ativan) and carbamazepine (Tegretol) in alcoholics who meet the criteria for a diagnosis of uncomplicated alcohol withdrawal syndrome. Participants are randomized to five days of treatment with a 1-week posttreatment followup. |
| NCT00005951 ↗ | Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma | Completed | National Cancer Institute (NCI) | Phase 1 | 2000-08-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma. |
| NCT00005951 ↗ | Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma | Completed | Duke University | Phase 1 | 2000-08-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma. |
| NCT00006395 ↗ | Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers | Completed | National Institutes of Health Clinical Center (CC) | Phase 4 | 2000-10-01 | St. John's Wort is a popular dietary supplement that many patients-including those with epilepsy or seizures-take in addition to their regular medicines to elevate mood or relieve stress. Preliminary research indicates that this supplement can speed the metabolism of the anti-seizure drug Tegretol, causing reduced blood levels of the drug. Patients who take Tegretol to control their seizures may have more frequent seizures if the blood level of the drug drops too low. A recent study shows that this effect is not seen when Tegretol is taken for at least 3 weeks. The present study will examine whether there is a medically important drug interaction between St. John's wort and Tegretol when Tegretol is taken for 1 day. Normal healthy volunteers between 21 and 65 years old who are not taking medicines that can affect the metabolism of drugs in the liver and have not used St. John's wort for at least 30 days may be eligible for this 25-day study. Participants will take a 400-mg dose of Tegretol after fasting overnight. Blood samples will be drawn the next day during a 12-hour clinic stay at the following intervals: just before the Tegretol dose and at 1, 2, 4, 6, 8, 10, 24, 34, 48 and 72 hours after the dose. A catheter will be placed in the vein to prevent the need for multiple needle sticks until after the 10-hour sample. After completing the blood sampling, participants will take 300 mg of St. John's wort 3 times a day with meals for 2 weeks. After 2 weeks, another fasting dose of Tegretol will be given and the 72-hour blood study will be repeated. This study may provide information important for the care of patients with epilepsy who take both Tegretol and St. John's Wort. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TEGRETOL-XR
Condition Name
Clinical Trial Locations for TEGRETOL-XR
Trials by Country
Clinical Trial Progress for TEGRETOL-XR
Clinical Trial Phase
Clinical Trial Sponsors for TEGRETOL-XR
Sponsor Name
